SEC Comment Letter 0000000000-24-010420 to LENZ Therapeutics, Inc. (LENZ)
LENZ Therapeutics, Inc.
Date: Sept. 13, 2024 · CIK: 0001815776 · Accession: 0000000000-24-010420
AI Filing Summary & Sentiment
File numbers found in text: 333-282036
Letter
September 13, 2024 Evert Schimmelpennink President and Chief Executive Officer LENZ Therapeutics, Inc. 201 Lomas Santa Fe Dr., Suite 300 Solana Beach, California 92075 Re:LENZ Therapeutics, Inc. Registration Statement on Form S-1 Filed September 11, 2024 File No. 333-282036 Dear Evert Schimmelpennink: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Dan Koeppen, Esq.
Show Raw Text
September 13, 2024
Evert Schimmelpennink
President and Chief Executive Officer
LENZ Therapeutics, Inc.
201 Lomas Santa Fe Dr., Suite 300
Solana Beach, California 92075
Re:LENZ Therapeutics, Inc.
Registration Statement on Form S-1
Filed September 11, 2024
File No. 333-282036
Dear Evert Schimmelpennink:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at 202-551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Dan Koeppen, Esq.